# Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

> **NCT05762536** · PHASE2 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 245 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Docetaxel or cabazitaxel

## Key facts

- **NCT ID:** NCT05762536
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2027-05
- **Final completion:** 2028-05
- **Target enrollment:** 245 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762536, "Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05762536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*